MedTrace Logo

Gefitinib for EGFR Sensitive Mutation Postoperative Stage Ib NSCLC Patients

NCT02526537 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2017-12-18

No results posted yet for this study

Summary

Currently, whether adjuvant therapy should be applied to Stage Ib non-small cell lung cancer (NSCLC) patients who received radical resection remains controversial. There is still no clear evidence that the postoperative adjuvant chemotherapy or other treatments can improve the survival rate for patients with stage Ib NSCLC. Tyrosine Kinase Inhibitors (TKIs) such as Gefitinib and Erlotinib are widely accepted as the first-line therapy for Epidermal growth factor receptor (EGFR) gene mutation late stage NSCLC patients. However the effect is largely uncertain for early stage patients who received surgery. The investigators aim to evaluate the effect of postoperative adjuvant use of Gefitinib for high risk stage Ib EGFR sensitive mutation NSCLC patients.

Conditions

Sponsors & Collaborators

  • Lunxu Liu

    lead OTHER

Principal Investigators

  • Lunxu Liu, Professor · West China Hospital

Eligibility

Min Age
18 Years
Max Age
78 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-11
Primary Completion
2016-06-07
Completion
2016-06-07

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02526537 on ClinicalTrials.gov